Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
Recognized from query: venetoclax. Matching terms were moved into the structured fields above when recognized.
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "venetoclax" Clear all
Active, not recruiting Phase 1 Interventional

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

NCT03844815
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine, Venetoclax
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
Venetoclax, Azacitidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
58
States / cities
Fullerton, California • Los Angeles, California • Torrance, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

NCT07014917
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL Variant
Interventions
Venetoclax, Acalabrutinib
Drug
Lead sponsor
Zulfa Omer
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
865
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 553 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

NCT03713580
View directory record Official record
Conditions
Non-hodgkin Lymphoma
Interventions
Venetoclax
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

NCT05951959
View directory record Official record
Conditions
Mantle Cell Lymphoma (MCL)
Interventions
Acalabrutinib, Venetoclax, Rituximab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Hackensack, New Jersey • Stony Brook, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

NCT03801525
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib, Venetoclax
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT04655755
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine and Cedazuridine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

NCT03113422
View directory record Official record
Conditions
Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
Interventions
Induction Venetoclax, Maintenance Venetoclax
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Atlanta, Georgia • Baltimore, Maryland • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jul 24, 2026, 5:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

NCT03523975
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Venetoclax, Lenalidomide, Rituximab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

NCT01211457
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
sapacitabine and decitabine (Part 1 - completed), sapacitabine and venetoclax (Part 2 - recruiting)
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Jul 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

NCT04887857
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
CC-486, Venetoclax
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Jul 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

NCT02670044
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cobimetinib, Idasanutlin, Venetoclax
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Jul 24, 2026, 5:32 AM EDT
Withdrawn Phase 1 Interventional

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06007911
View directory record Official record
Conditions
Relapsed Adult AML, Refractory AML
Interventions
Navitoclax Dose Level 1, Navitoclax Dose Level 0, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venetoclax Dose Levels 0 to 2, Cladribine, Cytarabine (Cladribine Low Dose Cytarabine Backbone), Cytarabine (CLAG-M Backbone), Mitoxantrone, Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jul 24, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

NCT06508489
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
SAR443579, venetoclax, azacitidine
Biological · Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Duarte, California • The Bronx, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 24, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

NCT02639910
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Tafasitamab, Idelalisib, Venetoclax
Biological · Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Jul 24, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
167
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 136 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

NCT04372433
View directory record Official record
Conditions
AML With Monocytic Differentiation, CMML
Interventions
IO-202, IO-202 and Azacitidine, IO-202 and Azacitidine + Venetoclax
Biological
Lead sponsor
Immune-Onc Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Davis, California • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 1 Interventional

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

NCT04447716
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
Interventions
Venetoclax, Lenalidomide, Rituximab, Rituximab and Hyaluronidase Human
Drug · Biological
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 24, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT06520098
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
San Francisco, California • Kansas City, Missouri • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 24, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT04905407
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tamibarotene, Venetoclax, Azacitidine
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 1 Interventional

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

NCT06445907
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax, Q702
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 5:32 AM EDT
Active, not recruiting Phase 1 Interventional

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

NCT05001828
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years to 99 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Miami, Florida • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 24, 2026, 5:32 AM EDT